Emergent (EBS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$770.2M

Revenue (quarter)

$234.3M

Revenue growth (year over year)

+66.29%

Gross profit (trailing twelve months)

$430.3M

Gross margin

55.87%

Net income (trailing twelve months)

−$176.8M

Net income (quarter)

−$180.2M

Net income growth (year over year)

−1401.67%

Net margin

−22.96%

Return on equity

−40.29%

EPS (trailing twelve months)

−$3.40

Book value per share

$6.65

P/E (trailing twelve months)

—

Price to book

1.04

Debt to assets

69.43%

Payout ratio

—

Dividend yield

—

Company profile

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

• Is Emergent (EBS) profitable?

  No. Emergent reported a net loss of $176.8M over the trailing twelve months.

• How much revenue does Emergent (EBS) make?

  Emergent generated $770.2M in revenue over the trailing twelve months, up 66.29% year over year.

• How do I buy stock in Emergent (EBS)?

  EBS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.